Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,960
datasets available to search
ShareScore release 0.9.0
Dataset results
3,960 results for “lung patient”
Novel Pulmonary Imaging Biomarkers and Cutaneous Gene Expression Subsetting for Patient Selection and Outcome Assessment in the Dasatinib Treatment of Systemic Sclerosis-associated Interstitial Lung D
GEO Series GSE79387. Homo sapiens. 45 samples. Type: Expression profiling by array.
Clinical and Immunological Responses to Combined JAK Inhibition and PD-1 immunotherapy for Lung Cancer Patients
GEO Series GSE266219. Homo sapiens. 79 samples. Type: Expression profiling by high throughput sequencing.
Global Gene Expression Profiles of Fibroblasts from the Lungs of Patients with Idiopathic Pulmonary Fibrosis: The Role of CCL8
GEO Series GSE71351. Homo sapiens. 12 samples. Type: Expression profiling by array.
DNA copy number profiling of lung adenocarcinomas and patient-matched non-malignant lung
GEO Series GSE139294. Homo sapiens. 166 samples. Type: Genome variation profiling by SNP array.
A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer
GEO Series GSE6253. Homo sapiens. 72 samples. Type: Expression profiling by array.
Stimulation by LPS and HMGB1 in peripheral blood neutrophils from patients with sepsis-induced acute lung injury
GEO Series GSE3037. Homo sapiens. 24 samples. Type: Expression profiling by array.
raw data related to project "Circulating biomarkers as predictors of gender-specific response to Immune Checkpoint Inhibitors in melanoma and non-small-cell lung cancer patients"
<p><strong>Sex-related differences in serum biomarker levels predict the activity and efficacy of Immune Checkpoint Inhibitors in advanced melanoma and Non-Small Cell Lung Cancer patients.</strong></p> <p><strong>Abstract </strong></p> <p><strong>Background:</strong> Immune Checkpoint Inhibitors (ICIs) lead to durable response and a significant increase in long-term survival in patients with advanced malignant melanoma (MM) and Non-Small Cell Lung Cancer (NSCLC). The identification of serum cytokines that can predict their activity and efficacy, and their sex interaction, could improve treatment personalization. </p> <p><strong>Methods: </strong>In this prospective study, we enrolled immunotherapy-naïve patients affected by advanced MM and NSCLC treated with ICIs. The primary endpoint was to dissect the potential sex correlations between serum cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, MCP-1, TNF-ɑ, IP-10, VEGF, sPD-L1) and the overall response rate (ORR). Secondly, we analyzed biomarker changes during treatment related to ORR, disease control rate (DCR), progression free survival (PFS) and overall survival (OS). Blood samples, collected at baseline and during treatment until disease progression (PD) or up to 2 years, were analyzed using Luminex xMAP or ELLA based technology. </p> <p>Three Luminex xMAP assays and two ELLA microfluidic cartridges were used to screen 28 immune-related biomarkers in 38 paired serum and citrate-theophylline-adenosine-dipyridamole (CTAD) plasma samples collected from 10 advanced melanoma or non-small cell lung cancer (NSCLC) patients at different time points during immunotherapy.</p> <p><strong>Results</strong>: Serum samples from 161 patients (98 males/63 females; 92 MM/69 NSCLC) were analyzed for treatment response. At baseline, IL-6 was significantly lower in females (F) <em>versus</em> males (M); lower levels of IL-4 in F and of IL-6 in both sexes significantly correlated with a better ORR, while higher IL-4 and TNF-ɑ values were predictive of a lower probability of ORR in F <em>versus</em> M. One hundred and sixty-five patients were evaluable for survival analysis: at multiple Cox regression, an increased risk of PD was observed in F with higher baseline values of IL-4, sPD-L1 and IL-10, while higher IL-6 was a negative predictor in males. In males, higher levels of GM-CSF predict a longer survival, whereas higher IL-1β predicts a shorter survival. Regardless of sex, high baseline IL-8 values were associated with an increased risk of both PD and death, and high IL-6 levels only with shorter OS. </p> <p>Twenty-three of 28 biomarkers were detected both in serum and plasma by at least one of the assays, including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, GM-CSF, IFN-γ, TNF-α, VEGF, IP-10, MCP-1, eotaxin, fractalkine, G-CSF, IFN-α, IL-1RA, IL-13, IL-17A, MIP-1β and sPD-L1. Conversely, FGF-2 and IL-1α were not detected in both matrices; GRO-α factor and EGF were detected only in serum and MIP-1α only in plasma. sPD-L1, MCP-1, IFN-γ, IL-8, MIP-1β and VEGF were, respectively, 1.15-, 1.44-, 1.83-, 2.43-, 2.82-, 6.72-fold higher in serum, whereas IL-10, IL-4, IL-2 and IL-5 were 1.05-, 1.19-, 1.92- and 2.17-fold higher, respectively, in plasma. IP-10 levels were higher in plasma but, as well as for VEGF, the bias serum versus plasma varied depending on the assay used (IP-10: −5.7% to −145%; VEGF: 115% to 165%). No significant differences were found for the remaining nine analyzed cytokines.</p> <p><strong>Conclusions</strong></p> <p>Serum IL-1β, IL-4, IL-6, IL-10, GM-CSF, TNFɑ, and sPDL1 had a significant independent sex-related predictive impact on ORR, PFS and OS in melanoma and NSCLC patients treated with ICIs. These results will potentially pave the way for new ICI combinations, designed according to baseline and early changes of these cytokines and stratified by sex. </p> <p>The cytokine and sPD-L1 levels may differ between serum and plasma samples collected from cancer patients treated with immunotherapy, and the results obtained can be influenced by the different characteristics of the tested assays.</p>
Medsensio-Sanolla Cardiopulmonary Auscultation Dataset [MSCAD] - a dataset of lung & heart auscultation recordings as well as vitals data for COVID and chronic patients
<p>This is a comprehensive clinical database that contains information from confirmed COVID-19 patients, individuals who are at higher risk for severe COVID-19, and healthy patients. The data was collected as part of the [PyxY.ai project](https://pyxy.ai/), which is funded under the Horizon 2020 program. The dataset has been collected specifically to aid in the development of the PyXy.ai system.</p> <p>The dataset consists of two parts: first part contains 18497 auscultation recordings collected during 1875 encounters with 1333 patients (among the patients: 185 had COPD, 73 had Asthma, 33 had emphysema, 739 had hypertension, 123 had myocardial infarction, 213 had heart failure); the second part consists of 4547 audio recordings collected in 319 encounters with 319 patients (1 encounter per patient). In the first part, 60% of recordings corresponds to pulmonary auscultation (in standard locations: left and right: main bronchus, basal segment of lung, apical segment of upper lobe of lung), 40% to cardiac auscultation (aortic valve, pulmonary valve, tricuspid valve, mitral valve). In the second dataset 100% of recordings corresponds to pulmonary auscultation - this part contains solely pulmonary auscultation recordings. In case of both datasets some vitals data for patients is also provided (i.a., heart rate, blood pressure, pulse oximetry, body temperature). Audio recordings are provided in wav format, vitals data in CSV format as well as HL7 FHIR format.</p> <p>"Medsensio-Sanolla Cardiopulmonary Auscultation Dataset [MSCAD] - a dataset of lung & heart auscultation recordings as well as vitals data for COVID and chronic patients." (c) 2023 by Medsensio AS, Sanolla Ltd, Rudolf Riester GmbH, Helgeland hospital trust / Helgelandssykehuset HF, Philonmed GmbH, Benevit holding GmbH, Natali Ltd.</p> <p>"Medsensio-Sanolla Cardiopulmonary Auscultation Dataset [MSCAD] - a dataset of lung & heart auscultation recordings as well as vitals data for COVID and chronic patients." is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 Unported License.</p> <p>You should have received a copy of the license along with this work. If not, see <http://creativecommons.org/licenses/by-nc-sa/4.0/>.</p>
Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030
ClinicalTrials.gov study NCT00899535. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00748163. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study of Smoking Trajectory in Newly Diagnosis Lung Cancer Patients
ClinicalTrials.gov study NCT03642041. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy
ClinicalTrials.gov study NCT02805062. IPD Sharing: NO. Countries: 0. Publications: 0.
Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool
ClinicalTrials.gov study NCT02172027. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
ClinicalTrials.gov study NCT00103714. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Evaluation of Novel Lung Function Parameters in Patients With Bronchial Asthma
ClinicalTrials.gov study NCT03820427. IPD Sharing: NO. Countries: 0. Publications: 0.
SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
ClinicalTrials.gov study NCT07272057. IPD Sharing: NO. Countries: 0. Publications: 0.
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00934076. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation
ClinicalTrials.gov study NCT02827357. IPD Sharing: NO. Countries: 0. Publications: 0.
4D Image-guided Adaptive Radiotherapy for Lung Cancer: Patient Image Acquisition
ClinicalTrials.gov study NCT01018147. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Biomarkers Predicting Response in Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride
ClinicalTrials.gov study NCT01123460. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.